Select your language

Investor Relations

Key Share Information

Trading Symbol: T9G

ISIN: GB00BM9XQ619

WKN: A3DTUQ

LEI: 875500BCH1T6XX5EUG13

Exchanges: Hamburg, Stuttgart, Düsseldorf

Trading Venues: Xetra and Tradegate

Investor Contact: investors@vidacpharma.com

Securities Prospectus 2025

To access the securities prospectus and summary documents, please read and accept the disclaimer below.

Corporate Governance

Access our Articles of Association and corporate governance documents.

Download Articles of Association

Financial Calendar

Upcoming Events

First patient dosed in Phase 2B* on highly proliferative AK lesions February 2026
Filing with OTC Markets for trading in the USA February 2026
Filing for admission to Quest for Health Accelerator (Strasbourg, France) February 2026
View All Upcoming Financial Events
Healthtech Global Summit Basel 3–5 March 2026
HNWI Non-Deal Roadshow (Frankfurt, Hamburg, Munich, Vienna) March 2026
Facts on Video with Lyndsay Malchuk April 2026
Admission to Quest for Health Accelerator (Strasbourg, France) May 2026
Clinical interim update May 2026
Publication of audited annual consolidated financial report for the year ended 31 December 2025 30 June 2026
Publication of unaudited condensed consolidated interim financial statements for the six months ended 30 June 2026 30 September 2026
Past Financial Events
Publication of company's prospectus 24 November 2025
Submission of application for including the company's shares in trading on the Düsseldorf Stock Exchange open market 24 November 2025
Virtual Conference with 850 investors on IIF 3 December 2025
Initiation of Phase 2B* clinical trial at CentroDerm (Germany) December 2025

Investment Overview

  • USD 22.8M invested by private investors since 2012 (founders and venture capital)
  • USD 4.9M invested by CSO and Innovation Authorities (non-dilutive grants)
  • Listed on the Hamburg, Stuttgart and Düsseldorf Stock Exchanges and traded on Xetra and Tradegate under a securities prospectus authorized by the German regulator BaFin
  • Winner of the Seal of Excellence from Horizon Europe EIC
  • In 2019, Max Herzberg and Yochai Richter acquired the shares held by the venture capital group through a management buyout
  • From 2019, the company has been funded by shareholders and management investments

Disclaimer

The following information does not constitute an public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.